News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
This marks Glenmark's first synthetic decapeptide injectable approval
The company plans to enter the EU markets in FY22
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
India sales grew 23.5% YoY with consolidation of Wockhardt products
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Subscribe To Our Newsletter & Stay Updated
